Yenny Zhang is Crafting a Distinct Narrative in Retail Design

Yenny Zhang is a dynamic retail designer who shapes immersive experiences with a unique blend of creativity and spatial expertise.

Yenny Zhang, a dynamic retail designer, is gaining recognition for her efforts in shaping immersive experiences that defy convention. Yenny Zhang brings a unique approach to her role. She not only designs seasonal retail spaces for Nike but also crafts compelling brand designs for clients and visually striking music videos for artists.

With an academic foundation in Environmental Design from the prestigious ArtCenter College of Design, Yenny’s distinctive skill set integrates creativity, spatial expertise, and a playful, experimental spirit. Her philosophy revolves around infusing playfulness into every audience, creating retail spaces that transcend mere transactions and evolve into captivating narratives.

Yenny’s noteworthy contributions to several Nike campaigns, including the Women’s World Cup 2023, Air Max Day 2023, Future Fitness, and World Cup 2022, showcase her ability to integrate creative branding into spatial experience design seamlessly. Her work is not just about showcasing products but crafting immersive stories that resonate profoundly with the audience.

Beyond her creative work for Nike, Yenny has collaborated with high-profile clients and artists, including Complex Media, 8UCK, Warner Music China, and Milly Rock Group. She has applied her creative touch to various projects, from internship to commercial design. Notably, her work on the Nike Capsule, a post-COVID reflection, and Genesis Oasis, a sponsored project focusing on the reconnecting of humans and nature, demonstrates her ability to address societal shifts through design.

Yenny’s projects extend beyond the traditional boundaries of retail, with highlights such as Upyard, her degree project, introducing a futuristic retail system that immerses consumers deeply in brand experiences. Her work showcases creativity, functionality, and a forward-thinking vision.

Yenny Zhang navigates the intersection of creative branding and spatial experience design, shaping immersive storytelling,” says one of Yenny’s coworkers. “Her approach has elevated the retail experience, turning the space into a unique and unforgettable journey.

In addition to her impactful projects, Yenny has received accolades and recognitions, including being the gold winner of the London Design Awards and being selected for the C-IDEA Design Award.

As a designer, Yenny Zhang’s impact goes beyond the physical spaces she creates. Her multidimensional approach to design extends into typography, motion graphics, sustainability, and hospitality. Notable projects like Dust, an exploration of Dyson’s products, and ReGene Resort, a sustainable spa resort, underscore her commitment to holistic and meaningful design.

Yenny Zhang’s work at the intersection of retail, branding, and immersive experiences is redefining the industry and setting a new standard for creative excellence. With a portfolio spanning from major global campaigns to innovative personal projects, Yenny continues to shape the future of retail design with a playful spirit and a commitment to transformative storytelling.

Users can visit the portfolio website of Yenny Zhang ydesignspaces.com, for any media or commercial inquiries.

For updates, follow Yenny Zhang on Instagram: https://www.instagram.com/ydesignspaces/

Media Contact
Company Name: ydesignspaces
Contact Person: Yenny Zhang
Email: Send Email
City: Los Angeles
State: CA
Country: United States
Website: ydesignspaces.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Yenny Zhang is Crafting a Distinct Narrative in Retail Design

Latest Developments in Dry Eye Disease Pipeline – FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Leading Companies AbbVie, Allergan, AFT Pharma, Akorn, Alcon, Bausch Health, J&J

“Dry Eye Disease Pipeline”

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Dry Eye Disease pipeline constitutes 45+ key companies continuously working towards developing 50+ Dry Eye Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Dry Eye Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Dry Eye Disease Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Dry Eye Disease Market.

 

Some of the key takeaways from the Dry Eye Disease Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Dry Eye Disease treatment therapies with a considerable amount of success over the years. 
  • Dry Eye Disease companies working in the treatment market are Quorum Innovations, Serentrix, IVIEW Therapeutics, Taejoon Pharmaceutical, Seinda Pharmaceutical, Invirsa, GL Pharm Tech Corporation, Dreamhawk Vision Biotech, Inc, Aramis Biosciences, Kowa Company, Alcon, HanAll Biopharma, Seikagaku Corporation, Novaliq GmbH, and others, are developing therapies for the Dry Eye Disease treatment 
  • Emerging Dry Eye Disease therapies in the different phases of clinical trials are- Qi 401, SER-114, iVIEW 1001, TJO-083, SY-201, INV-102, GLH8NDE, SHJ 002, A197, K-161, AR-15512, HL036, SI-614, NOV03, CyclASol, and others are expected to have a significant impact on the Dry Eye Disease market in the coming years.   
  • In February 2023, “Novaliq revealed intentions to submit a Marketing Authorization Application (MAA) for CyclASol (ciclosporin ophthalmic solution), an innovative anti-inflammatory remedy aimed at addressing dry eye disease (DED) within the European Union.”
  • In November 2022, “Alcon declared the successful finalization of its acquisition of Aerie Pharmaceuticals. This acquisition has broadened Alcon’s portfolio with commercial products including netarsudil and latanoprost ophthalmic solution (Rocklatan) 0.02%/0.005% and netarsudil ophthalmic solution (Rhopressa) 0.02%, alongside AR-15512, a Phase 3 product in development for treating dry eye disease.”
  • In October 2022, “Aldeyra Therapeutics, Inc. concluded the phase 3 clinical study involving 0.25% reproxalap ophthalmic solution, an experimental medication under investigation for allergic conjunctivitis treatment. The company showcased the trial’s clinical findings at the American Academy of Optometry’s 2022 Annual Meeting.”
  • In October 2022, “Novaliq revealed that the U.S. Food and Drug Administration (FDA) had approved the New Drug Application (NDA) for CyclASol® (cyclosporine ophthalmic solution), an innovative anti-inflammatory remedy specifically designed to address the signs and symptoms of dry eye disease (DED). In the United States, the FDA has established a Prescription Drug User Fee Act (PDUFA) target action date for the CyclASol® New Drug Application (NDA).”
  • In November 2022, “Aerie Pharmaceuticals commenced a year-long, multicenter, double-masked, randomized Phase 3 trial, conducted at around 10 locations across the United States. All participants included in the study will be diagnosed with dry eye disease (DED). The trial will involve visits at Baseline (Day 1) as well as on Day 14, Day 90, Day 180, Day 270, and Day 365 (Study Exit).”
  • In January 2022, “NovaBay Pharmaceuticals introduced Avenova lubricating eye drops designed to address symptoms associated with dry eyes.”

 

Dry Eye Disease Overview

A lack of tear film homeostasis is the cause of dry eye disease (DED), also referred to as dry eye syndrome (DES), keratoconjunctivitis sicca (KCS), and keratitis sicca. DED is a multifactorial illness of the ocular surface.

 

Get a Free Sample PDF Report to know more about Dry Eye Disease Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/dry-eye-disease-pipeline-insight

 

Emerging Dry Eye Disease Drugs Under Different Phases of Clinical Development Include:

  • Qi 401: Quorum Innovations
  • SER-114: Serentrix
  • iVIEW 1001: IVIEW Therapeutics
  • TJO-083: Taejoon Pharmaceutical
  • SY-201: Seinda Pharmaceutical
  • INV-102: Invirsa
  • GLH8NDE: GL Pharm Tech Corporation
  • SHJ 002: Dreamhawk Vision Biotech, Inc
  • A197: Aramis Biosciences
  • K-161: Kowa Company
  • AR-15512: Alcon
  • HL036: HanAll Biopharma
  • SI-614: Seikagaku Corporation
  • NOV03: Novaliq GmbH
  • CyclASol: Novaliq GmbH

 

Dry Eye Disease Route of Administration

Dry Eye Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

 

Dry Eye Disease Molecule Type

Dry Eye Disease Products have been categorized under various Molecule types, such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

 

Dry Eye Disease Pipeline Therapeutics Assessment

  • Dry Eye Disease Assessment by Product Type
  • Dry Eye Disease By Stage and Product Type
  • Dry Eye Disease Assessment by Route of Administration
  • Dry Eye Disease By Stage and Route of Administration
  • Dry Eye Disease Assessment by Molecule Type
  • Dry Eye Disease by Stage and Molecule Type

 

DelveInsight’s Dry Eye Disease Report covers around 50+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Dry Eye Disease product details are provided in the report. Download the Dry Eye Disease pipeline report to learn more about the emerging Dry Eye Disease therapies

 

Some of the key companies in the Dry Eye Disease Therapeutics Market include:

Key companies developing therapies for Dry Eye Disease are – AbbVie Inc. (Allergan PLC), AFT Pharmaceuticals, Akorn, Alcon Inc., Bausch Health Companies Inc., Horus Pharma, Johnson & Johnson, Mitotech, Novaliq GmbH, OASIS Medical, Otsuka Pharmaceutical Co. Ltd, Prestige Consumer Healthcare, Santen Pharmaceutical Co. Ltd, Sentiss Pharma Pvt. Ltd, Sun Pharmaceutical Industries Ltd, VISUfarma, and others.

 

Dry Eye Disease Pipeline Analysis:

The Dry Eye Disease pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Dry Eye Disease with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dry Eye Disease Treatment.
  • Dry Eye Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Dry Eye Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dry Eye Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Dry Eye Disease drugs and therapies

 

Dry Eye Disease Pipeline Market Drivers

  • Rise in geriatric population, increasing Exposure to computer screens, increased R&D Activities, adoption of new Technologies are some of the important factors that are fueling the Dry Eye Disease Market.

 

Dry Eye Disease Pipeline Market Barriers

  • However, lack of awareness about dry eye disease in low income countries, complexity of the disease, challenges associated with the Ocular drug delivery and other factors are creating obstacles in the Dry Eye Disease Market growth.

 

Scope of Dry Eye Disease Pipeline Drug Insight    

  • Coverage: Global
  • Key Dry Eye Disease Companies: Quorum Innovations, Serentrix, IVIEW Therapeutics, Taejoon Pharmaceutical, Seinda Pharmaceutical, Invirsa, GL Pharm Tech Corporation, Dreamhawk Vision Biotech, Inc, Aramis Biosciences, Kowa Company, Alcon, HanAll Biopharma, Seikagaku Corporation, Novaliq GmbH, and others
  • Key Dry Eye Disease Therapies: Qi 401, SER-114, iVIEW 1001, TJO-083, SY-201, INV-102, GLH8NDE, SHJ 002, A197, K-161, AR-15512, HL036, SI-614, NOV03, CyclASol, and others
  • Dry Eye Disease Therapeutic Assessment: Dry Eye Disease current marketed and Dry Eye Disease emerging therapies
  • Dry Eye Disease Market Dynamics: Dry Eye Disease market drivers and Dry Eye Disease market barriers 

 

Request for Sample PDF Report for Dry Eye Disease Pipeline Assessment and clinical trials

 

Table of Contents

1. Dry Eye Disease Report Introduction

2. Dry Eye Disease Executive Summary

3. Dry Eye Disease Overview

4. Dry Eye Disease- Analytical Perspective In-depth Commercial Assessment

5. Dry Eye Disease Pipeline Therapeutics

6. Dry Eye Disease Late Stage Products (Phase II/III)

7. Dry Eye Disease Mid Stage Products (Phase II)

8. Dry Eye Disease Early Stage Products (Phase I)

9. Dry Eye Disease Preclinical Stage Products

10. Dry Eye Disease Therapeutics Assessment

11. Dry Eye Disease Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Dry Eye Disease Key Companies

14. Dry Eye Disease Key Products

15. Dry Eye Disease Unmet Needs

16 . Dry Eye Disease Market Drivers and Barriers

17. Dry Eye Disease Future Perspectives and Conclusion

18. Dry Eye Disease Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Latest Developments in Dry Eye Disease Pipeline – FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Leading Companies AbbVie, Allergan, AFT Pharma, Akorn, Alcon, Bausch Health, J&J

Influenza Pipeline Report: Recent Approvals by FDA, EMA, and PMDA, Emerging Therapies, Clinical Trials, and Growth Outlook | AlloVir, Osivax, CureVac AG, GlaxoSmithKline, Cocrystal Pharma Inc.

“Influenza Pipeline”

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Influenza pipeline constitutes 120+ key companies continuously working towards developing 120+ Influenza treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Influenza Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Influenza Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Influenza Market.

 

Some of the key takeaways from the Influenza Pipeline Report: 

  • Companies across the globe are diligently working toward developing novel Influenza treatment therapies with a considerable amount of success over the years. 
  • Influenza companies working in the treatment market are Arcturus Therapeutics, Emergex Vaccines, Emergent Biosolutions, Cocrystal Pharma Inc, GlaxoSmithKline, CureVac AG, AlloVir, Moderna, OSIVAX, Ena Respiratory, Valenta Pharmaceuticals, Raynovent Co., Ltd, and others, are developing therapies for the Influenza treatment 
  • Emerging Influenza therapies in the different phases of clinical trials are- LUNAR-FLU, naNO-Flu, UniFlu, CC-42344,GSK4382276A, CVSQIV, ALVR 106, mRNA-1073, OVX836, Neumifil, INNA-051, mRNA-1010, XC-221, ZSP1273, and others are expected to have a significant impact on the Influenza market in the coming years.   
  • In July 2022, Emergex Vaccines Holding Limited has achieved the production of its universal/pandemic influenza vaccine designed for Phase I clinical trials, utilizing fully synthetic CD8+ T cell Adaptive Vaccines.
  • CureVac has initiated the dosing of the initial participant in a Phase I trial for the modified influenza vaccine FLU SV mRNA, developed in partnership with GSK. This trial comes subsequent to the commencement of another Phase I study in February 2022, assessing an unmodified, multivalent influenza vaccine candidate, CVSQIV, across clinical sites in Panama. Both studies aim to present combined data upon completion.
  • In June 2022, Moderna, Inc. revealed the initiation of dosing in a Phase III trial for its seasonal influenza vaccine candidate, mRNA-1010, with the initial participants receiving doses. Anticipated to enroll about 6,000 adults in Southern Hemisphere nations, this Phase III randomized, observer-blind study aims to assess the safety and immune response of mRNA-1010 compared to a licensed seasonal influenza vaccine in adults aged 18 years and above.
  • In April 2022, Novavax, Inc. released preliminary findings from the Phase I/II clinical trial of its COVID-Influenza Combination Vaccine (CIC). The CIC merges Novavax’s COVID-19 vaccine, NVX-CoV2373, with its quadrivalent influenza vaccine candidate. The trial confirmed the viability of formulating this combined vaccine, showing good tolerance and immune response.
  • In April 2022, Osivax has announced the publication of Phase IIa results for its universal influenza vaccine candidate, OVX836, titled “Randomized, Double-Blind, Reference-Controlled, Phase IIa Study Evaluating the Immunogenicity and Safety of OVX836, A Nucleoprotein-Based Influenza Vaccine” in the journal Frontiers in Immunology. Utilizing Osivax’s self-assembling nanoparticle technology, OVX836 focuses on an internal nucleoprotein (NP), an antigen less prone to frequent mutations compared to surface antigens of the influenza virus.
  • BioNTech and Pfizer have joined forces to develop an influenza vaccine utilizing BioNTech’s mRNA platforms. In July 2022, data from the Phase II expansion study of BNT161 in participants aged 65 and older revealed initial evidence of significantly enhanced induction of strain-specific CD4+ and CD8+ responses. The geometric mean fold rise (GMFR) was notably higher compared to the control quadrivalent influenza vaccine for both CD4+ and CD8+ strain-specific T cell responses. Encouraged by these promising T cell responses and observed seroconversion, plans are underway to commence a Phase III study for the quadrivalent modified mRNA influenza vaccine in the latter half of 2022.
  • In May 2022, Blue Water Vaccines revealed a partnership with the Center for R&D in Immunobiologics, part of the Instituto Butantan, to advance BWV’s universal influenza candidate, BWV-101, in Brazil. Butantan stands as the primary flu vaccine producer in the Southern Hemisphere, responsible for manufacturing all influenza vaccine doses employed by the Brazilian Ministry of Health.

 

Influenza Overview

A contagious virus that affects the upper respiratory system, including the upper and lower respiratory passages, called influenza.It is caused by a broad range of influenza viruses. While some of these viruses are unique to particular species, others can infect humans.

 

Get a Free Sample PDF Report to know more about Influenza Pipeline Therapeutic Assessment- 

https://www.delveinsight.com/report-store/influenza-pipeline-insight

 

Emerging Influenza Drugs Under Different Phases of Clinical Development Include:

  • LUNAR-FLU: Arcturus Therapeutics
  • naNO-Flu: Emergex Vaccines
  • UniFlu: Emergent Biosolutions
  • CC-42344: Cocrystal Pharma Inc
  • GSK4382276A: GlaxoSmithKline
  • CVSQIV: CureVac AG
  • ALVR 106: AlloVir
  • mRNA-1073: Moderna
  • OVX836: OSIVAX
  • Neumifil: Pneumagen Ltd.
  • INNA-051: Ena Respiratory
  • mRNA-1010: Moderna, Inc.
  • XC-221: Valenta Pharmaceuticals
  • ZSP1273: Raynovent Co., Ltd

 

Influenza Route of Administration

Influenza pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Inhalation
  • Inhalation/Intravenous/Oral
  • Intranasal
  • Intravenous
  • Intravenous/ Subcutaneous
  • NA
  • Oral
  • Oral/intranasal/subcutaneous
  • Parenteral
  • Subcutaneous

 

Influenza Molecule Type

Influenza Products have been categorized under various Molecule types, such as

  • Antibody
  • Antisense oligonucleotides
  • Immunotherapy
  • Monoclonal antibody
  • Peptides
  • Protein
  • Recombinant protein
  • Small molecule
  • Stem Cell
  • Vaccine

 

Influenza Pipeline Therapeutics Assessment

  • Influenza Assessment by Product Type
  • Influenza By Stage and Product Type
  • Influenza Assessment by Route of Administration
  • Influenza By Stage and Route of Administration
  • Influenza Assessment by Molecule Type
  • Influenza by Stage and Molecule Type

 

DelveInsight’s Influenza Report covers around 120+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Influenza product details are provided in the report. Download the Influenza pipeline report to learn more about the emerging Influenza therapies

 

Some of the key companies in the Influenza Therapeutics Market include:

Key companies developing therapies for Influenza are – AlloVir, Osivax, CureVac AG, GlaxoSmithKline, Cocrystal Pharma Inc, Viriom, Emergent BioSolutions, Pfizer, Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Guangdong Raynovent Biotech Co., Ltd, FluGen Inc, BlueWillow Biologics, AVM Biotechnology LLC, Ansun Biopharma, Inc., Guangzhou Henovcom Bioscience, Sunshine Lake Pharma Co., Ltd., Emergex Vaccines, Vir Biotechnology, CSL Limited, Novavax, Mitsubishi Chemical Group Corporation, Poolbeg Pharma, MYMETICS, CELLTRION INC, and others.

 

Influenza Pipeline Analysis:

The Influenza pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Influenza with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Influenza Treatment.
  • Influenza key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Influenza Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Influenza market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Influenza drugs and therapies

 

Influenza Pipeline Market Drivers

  • Increasing awareness by government authorities, increasing clinical trials for new product development, increase in investment by leading market players are some of the important factors that are fueling the Influenza Market.

 

Influenza Pipeline Market Barriers

  • However, longer process for novel vaccine development, high cost of vaccine development other factors are creating obstacles in the Influenza Market growth.

 

Scope of Influenza Pipeline Drug Insight    

  • Coverage: Global
  • Key Influenza Companies: Arcturus Therapeutics, Emergex Vaccines, Emergent Biosolutions, Cocrystal Pharma Inc, GlaxoSmithKline, CureVac AG, AlloVir, Moderna, OSIVAX, Ena Respiratory, Valenta Pharmaceuticals, Raynovent Co., Ltd, and others
  • Key Influenza Therapies: LUNAR-FLU, naNO-Flu, UniFlu, CC-42344,GSK4382276A, CVSQIV, ALVR 106, mRNA-1073, OVX836, Neumifil, INNA-051, mRNA-1010, XC-221, ZSP1273, and others
  • Influenza Therapeutic Assessment: Influenza current marketed and Influenza emerging therapies
  • Influenza Market Dynamics: Influenza market drivers and Influenza market barriers 

 

Request for Sample PDF Report for Influenza Pipeline Assessment and clinical trials

 

Table of Contents

1. Influenza Report Introduction

2. Influenza Executive Summary

3. Influenza Overview

4. Influenza- Analytical Perspective In-depth Commercial Assessment

5. Influenza Pipeline Therapeutics

6. Influenza Late Stage Products (Phase II/III)

7. Influenza Mid Stage Products (Phase II)

8. Influenza Early Stage Products (Phase I)

9. Influenza Preclinical Stage Products

10. Influenza Therapeutics Assessment

11. Influenza Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Influenza Key Companies

14. Influenza Key Products

15. Influenza Unmet Needs

16 . Influenza Market Drivers and Barriers

17. Influenza Future Perspectives and Conclusion

18. Influenza Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Influenza Pipeline Report: Recent Approvals by FDA, EMA, and PMDA, Emerging Therapies, Clinical Trials, and Growth Outlook | AlloVir, Osivax, CureVac AG, GlaxoSmithKline, Cocrystal Pharma Inc.

Assessment of Non-Hodgkin Lymphoma Pipeline and Clinical Trials in 2023: FDA Approvals, Therapeutics, and Key Companies by DelveInsight | AstraZeneca, Baxter, Bayer, Bristol Myers Squibb, Teva Pharma

“Non-Hodgkin Lymphoma Pipeline”

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Non-Hodgkin Lymphoma pipeline constitutes key companies continuously working towards developing Non-Hodgkin Lymphoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Non-Hodgkin Lymphoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Non-Hodgkin Lymphoma Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Non-Hodgkin Lymphoma Market.

 

Some of the key takeaways from the Non-Hodgkin Lymphoma Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Non-Hodgkin Lymphoma treatment therapies with a considerable amount of success over the years. 
  • Non-Hodgkin Lymphoma companies working in the treatment market are Autolus, Genor Biopharma, AbbVie/ Genmab, AstraZeneca, Jiangsu Hengrui Medicine, Pacylex Pharmaceuticals, Zentera Therapeutics, TCR2 Therapeutics, Artiva Biotherapeutics, Loxo Oncology, Angiocrine Bioscience, AbbVie, Novartis, and others, are developing therapies for the Non-Hodgkin Lymphoma treatment 
  • Emerging Non-Hodgkin Lymphoma therapies in the different phases of clinical trials are- AUTO4, GB226, Epcoritamab, Capivasertib, HRS-3738, PCLX-001, ZN-d5, TC-110, AB-101, LOXO-305, AB-205, Venetoclax, Tisagenlecleucel, and others are expected to have a significant impact on the Non-Hodgkin Lymphoma market in the coming years.   
  • In May 2023, The US FDA has granted approval for the investigational new drug (IND) application submitted by SIRPant Immuno therapeutics. This approval allows the commencement of a phase I clinical trial, marking the first time the treatment will be tested in humans, aimed at addressing relapsed refractory non-Hodgkin lymphoma.
  • In May 2023, The US FDA has granted approval to AbbVie for EPKINLY (epcoritamab-bysp), a T-cell engaging bispecific antibody designed for treating adult patients experiencing relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

 

Non-Hodgkin Lymphoma Overview

A malignancy of the lymphatic system is called non-Hodgkin’s lymphoma (NHL). It happens when lymphocytes give rise to tumors. One variety of white blood cell is the lymphocyte. NHL is more prevalent than lymphoma Hodgkin’s. The presence of a particular kind of aberrant cell known as the Reed-Sternberg cell is the primary distinction between NHL and Hodgkin’s lymphoma.

 

Get a Free Sample PDF Report to know more about Non-Hodgkin Lymphoma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/non-hodgkins-lymphoma-nhl-pipeline-insight 

 

Emerging Non-Hodgkin Lymphoma Drugs Under Different Phases of Clinical Development Include:

  • AUTO4: Autolus
  • GB226: Genor Biopharma
  • Epcoritamab: AbbVie/ Genmab
  • Capivasertib: AstraZeneca
  • HRS-3738: Jiangsu Hengrui Medicine
  • PCLX-001: Pacylex Pharmaceuticals
  • ZN-d5: Zentera Therapeutics
  • TC-110: TCR2 Therapeutics
  • AB-101: Artiva Biotherapeutics
  • LOXO-305: Loxo Oncology
  • AB-205: Angiocrine Bioscience
  • Venetoclax: AbbVie
  • Tisagenlecleucel: Novartis 

 

Non-Hodgkin Lymphoma Pipeline Therapeutics Assessment

  • Non-Hodgkin Lymphoma Assessment by Product Type
  • Non-Hodgkin Lymphoma By Stage and Product Type
  • Non-Hodgkin Lymphoma Assessment by Route of Administration
  • Non-Hodgkin Lymphoma By Stage and Route of Administration
  • Non-Hodgkin Lymphoma Assessment by Molecule Type
  • Non-Hodgkin Lymphoma by Stage and Molecule Type

 

DelveInsight’s Non-Hodgkin Lymphoma Report covers around products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Non-Hodgkin Lymphoma product details are provided in the report. Download the Non-Hodgkin Lymphoma pipeline report to learn more about the emerging Non-Hodgkin Lymphoma therapies

 

Some of the key companies in the Non-Hodgkin Lymphoma Therapeutics Market include:

Key Non-Hodgkin Lymphoma companies developing therapies for Non-Hodgkin Lymphoma are – AstraZeneca, Baxter International Inc., Bayer AG, Bristol Myers Squibb Company, Teva Pharmaceutical Industries Ltd, Eli Lilly and Co., F. Hoffmann La-Roche Ltd, GlaxoSmithKline PLC, and others.

 

Non-Hodgkin Lymphoma Pipeline Analysis:

The Non-Hodgkin Lymphoma pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Non-Hodgkin Lymphoma with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Hodgkin Lymphoma Treatment.
  • Non-Hodgkin Lymphoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Non-Hodgkin Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non-Hodgkin Lymphoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Non-Hodgkin Lymphoma drugs and therapies

 

Non-Hodgkin Lymphoma Pipeline Market Drivers

  • Increasing prevalence, ongoing and increased R&D activity, demand for innovative drugs and novel therapies are some of the important factors that are fueling the Non-Hodgkin Lymphoma Market.

 

Non-Hodgkin Lymphoma Pipeline Market Barriers

  • However, high cost of treatment, complications related to the drugs and other factors are creating obstacles in the Non-Hodgkin Lymphoma Market growth.

 

Scope of Non-Hodgkin Lymphoma Pipeline Drug Insight    

  • Coverage: Global
  • Key Non-Hodgkin Lymphoma Companies: Autolus, Genor Biopharma, AbbVie/ Genmab, AstraZeneca, Jiangsu Hengrui Medicine, Pacylex Pharmaceuticals, Zentera Therapeutics, TCR2 Therapeutics, Artiva Biotherapeutics, Loxo Oncology, Angiocrine Bioscience, AbbVie, Novartis, and others
  • Key Non-Hodgkin Lymphoma Therapies: AUTO4, GB226, Epcoritamab, Capivasertib, HRS-3738, PCLX-001, ZN-d5, TC-110, AB-101, LOXO-305, AB-205, Venetoclax, Tisagenlecleucel, and others
  • Non-Hodgkin Lymphoma Therapeutic Assessment: Non-Hodgkin Lymphoma current marketed and Non-Hodgkin Lymphoma emerging therapies
  • Non-Hodgkin Lymphoma Market Dynamics: Non-Hodgkin Lymphoma market drivers and Non-Hodgkin Lymphoma market barriers 

 

Request for Sample PDF Report for Non-Hodgkin Lymphoma Pipeline Assessment and clinical trials

 

Table of Contents

1. Non-Hodgkin Lymphoma Report Introduction

2. Non-Hodgkin Lymphoma Executive Summary

3. Non-Hodgkin Lymphoma Overview

4. Non-Hodgkin Lymphoma- Analytical Perspective In-depth Commercial Assessment

5. Non-Hodgkin Lymphoma Pipeline Therapeutics

6. Non-Hodgkin Lymphoma Late Stage Products (Phase II/III)

7. Non-Hodgkin Lymphoma Mid Stage Products (Phase II)

8. Non-Hodgkin Lymphoma Early Stage Products (Phase I)

9. Non-Hodgkin Lymphoma Preclinical Stage Products

10. Non-Hodgkin Lymphoma Therapeutics Assessment

11. Non-Hodgkin Lymphoma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Non-Hodgkin Lymphoma Key Companies

14. Non-Hodgkin Lymphoma Key Products

15. Non-Hodgkin Lymphoma Unmet Needs

16 . Non-Hodgkin Lymphoma Market Drivers and Barriers

17. Non-Hodgkin Lymphoma Future Perspectives and Conclusion

18. Non-Hodgkin Lymphoma Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Assessment of Non-Hodgkin Lymphoma Pipeline and Clinical Trials in 2023: FDA Approvals, Therapeutics, and Key Companies by DelveInsight | AstraZeneca, Baxter, Bayer, Bristol Myers Squibb, Teva Pharma

Projected Surge in Psychosis in Parkinson’s and Alzheimer’s Disease Market from 2023 to 2032: Analysis by DelveInsight on Sunovion Pharmaceuticals and Vanda Pharma

“Psychosis in Parkinson’s and Alzheimer’s Disease Market”

DelveInsight’s “Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Psychosis in Parkinson’s Disease and Alzheimer’s Disease, historical and forecasted epidemiology as well as the Psychosis in Parkinson’s Disease and Alzheimer’s Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Psychosis in Parkinson’s Disease and Alzheimer’s Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Forecast

 

Some of the key facts of the Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Report: 

  • The Psychosis in Parkinson’s Disease and Alzheimer’s Disease market size was valued approximately USD 1,229 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • Acadia’s NUPLAZID (pimavanserin) stands as the sole approved product for PDP (Parkinson’s Disease Psychosis) in the US. While it is still under investigation for ADP (Alzheimer’s Disease Psychosis), it carries a boxed warning concerning heightened mortality risks observed in elderly patients with psychosis related to dementia.
  • Several medications are in various stages of development to address psychosis in Parkinson’s Disease and Alzheimer’s Disease, yet only a limited number are in advanced stages. Examples include Karuna Therapeutics’ KarXT (xanomeline-trospium), Sunovion Pharmaceuticals’ Ulotaront (SEP-363856), and Vanda Pharmaceuticals’ FANAPT (iloperidone). These are expected to be introduced to the market within the forecast period spanning from 2023 to 2032.
  • In 2022, the combined diagnosed prevalent cases of Psychosis in PD (Parkinson’s Disease) and AD (Alzheimer’s Disease) across the 7MM reached around 6,737,337 cases. Projections indicate an anticipated increase by 2032 at a Compound Annual Growth Rate (CAGR) of 2.4% throughout the study period from 2019 to 2032.
  • In 2022, the United States represented approximately 34% of the diagnosed prevalent cases of Psychosis in PD (Parkinson’s Disease) and AD (Alzheimer’s Disease) within the 7MM. This proportion is anticipated to rise further by the year 2032.
  • In the United States, there were an estimated 675,948 cases in males and 503,305 cases in females affected by PD (Parkinson’s Disease) in 2022. These figures are projected to rise by the year 2032
  • In the year 2022, the number of AD (Alzheimer’s Disease) cases among males in EU4 and the UK was approximately 1,454,541, while among females, it reached nearly 3,487,835 cases. These figures are anticipated to increase by the year 2032.
  • In 2022, Germany contributed to roughly 18% of the total diagnosed prevalent cases of PD (Parkinson’s Disease) within the 7MM. These cases are projected to rise at a Compound Annual Growth Rate (CAGR) of 1.7% during the study period from 2019 to 2032.
  • Key Psychosis in Parkinson’s Disease and Alzheimer’s Disease Companies: Karuna Therapeutics, Sunovion Pharmaceuticals, Vanda Pharmaceuticals, Intra-Cellular Therapeutics, Merck Sharp & Dohme, and others
  • Key Psychosis in Parkinson’s Disease and Alzheimer’s Disease Therapies: KarXT, Ulotaront, FANAPT, ITI-1284, MK-8189, and others
  • The Parkinson’s Disease epidemiology based on gender analyzed that in the US, males diagnosed with PD are higher in number than females
  • The Psychosis in Parkinson’s Disease and Alzheimer’s Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Psychosis in Parkinson’s Disease and Alzheimer’s Disease pipeline products will significantly revolutionize the Psychosis in Parkinson’s Disease and Alzheimer’s Disease market dynamics.

 

Psychosis in Parkinson’s Disease and Alzheimer’s Disease Overview

The National Institute of Mental Health (NIMH) defines psychosis as a group of symptoms affecting the mind in which there has been a partial loss of reality awareness. People have disruptions in their thoughts and perceptions during a psychotic episode, making it difficult for them to distinguish between reality and illusion.

In Parkinson’s disease (PD) and Alzheimer’s disease (AD), psychosis develops as a result of both endogenous (associated with the disease process) and exogenous (drugs, for example).

 

Get a Free sample for the Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/psychosis-in-parkinsons-and-alzheimers-disease-market

 

Psychosis in Parkinson’s Disease and Alzheimer’s Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Psychosis in Parkinson’s Disease and Alzheimer’s Disease Epidemiology Segmentation:

The Psychosis in Parkinson’s Disease and Alzheimer’s Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Psychosis in Parkinson’s Disease and Alzheimer’s Disease
  • Prevalent Cases of Psychosis in Parkinson’s Disease and Alzheimer’s Disease by severity
  • Gender-specific Prevalence of Psychosis in Parkinson’s Disease and Alzheimer’s Disease
  • Diagnosed Cases of Episodic and Chronic Psychosis in Parkinson’s Disease and Alzheimer’s Disease

 

Download the report to understand which factors are driving Psychosis in Parkinson’s Disease and Alzheimer’s Disease epidemiology trends @ Psychosis in Parkinson’s Disease and Alzheimer’s Disease Epidemiology Forecast

 

Psychosis in Parkinson’s Disease and Alzheimer’s Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Psychosis in Parkinson’s Disease and Alzheimer’s Disease market or expected to get launched during the study period. The analysis covers Psychosis in Parkinson’s Disease and Alzheimer’s Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Psychosis in Parkinson’s Disease and Alzheimer’s Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Psychosis in Parkinson’s Disease and Alzheimer’s Disease Therapies and Key Companies

  • KarXT: Karuna Therapeutics
  • Ulotaront: Sunovion Pharmaceuticals
  • FANAPT: Vanda PharmaceuticalsF
  • ITI-1284: Intra-Cellular Therapeutics
  • MK-8189: Merck Sharp & Dohme

 

Discover more about therapies set to grab major Psychosis in Parkinson’s Disease and Alzheimer’s Disease market share @ Psychosis in Parkinson’s Disease and Alzheimer’s Disease Treatment Landscape

 

Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Strengths

  • Increased awareness and a more in-depth understanding of the disease pathophysiology has improved diagnosis and treatment.
  • The recent US FDA approval of NUPLAZID, the first approved therapy for treating hallucinations and delusions associated with PD Psychosis, indicates a positive change in treatment paradigm.

 

Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Opportunities

  • There are opportunities for pharma players to develop therapies with improved safety and tolerability profiles, effectively reducing symptoms and preventing the recurrence of Psychosis in PD and AD.
  • Advancement in biomarkers for cognitive decline allows precise diagnosis and individualized treatments

 

Scope of the Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Psychosis in Parkinson’s Disease and Alzheimer’s Disease Companies: Karuna Therapeutics, Sunovion Pharmaceuticals, Vanda Pharmaceuticals, Intra-Cellular Therapeutics, Merck Sharp & Dohme, and others
  • Key Psychosis in Parkinson’s Disease and Alzheimer’s Disease Therapies: KarXT, Ulotaront, FANAPT, ITI-1284, MK-8189, and others
  • Psychosis in Parkinson’s Disease and Alzheimer’s Disease Therapeutic Assessment: Psychosis in Parkinson’s Disease and Alzheimer’s Disease current marketed and Psychosis in Parkinson’s Disease and Alzheimer’s Disease emerging therapies
  • Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Dynamics: Psychosis in Parkinson’s Disease and Alzheimer’s Disease market drivers and Psychosis in Parkinson’s Disease and Alzheimer’s Disease market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Psychosis in Parkinson’s Disease and Alzheimer’s Disease Unmet Needs, KOL’s views, Analyst’s views, Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Access and Reimbursement 

 

To know more about Psychosis in Parkinson’s Disease and Alzheimer’s Disease companies working in the treatment market, visit @ Psychosis in Parkinson’s Disease and Alzheimer’s Disease Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Report Introduction

2. Executive Summary for Psychosis in Parkinson’s Disease and Alzheimer’s Disease

3. SWOT analysis of Psychosis in Parkinson’s Disease and Alzheimer’s Disease

4. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Patient Share (%) Overview at a Glance

5. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Overview at a Glance

6. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Disease Background and Overview

7. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Psychosis in Parkinson’s Disease and Alzheimer’s Disease 

9. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Current Treatment and Medical Practices

10. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Unmet Needs

11. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Emerging Therapies

12. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Outlook

13. Country-Wise Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Analysis (2019–2032)

14. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Access and Reimbursement of Therapies

15. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Drivers

16. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Barriers

17.  Psychosis in Parkinson’s Disease and Alzheimer’s Disease Appendix

18. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Projected Surge in Psychosis in Parkinson’s and Alzheimer’s Disease Market from 2023 to 2032: Analysis by DelveInsight on Sunovion Pharmaceuticals and Vanda Pharma

Assessment of RNA Interference Pipeline and Clinical Trials in 2023: FDA Approvals, Therapeutics, and Companies by DelveInsight | Moderna Therapeutics, GenSight Biologics, Pfizer, bluebird bio

“RNA Interference Pipeline”

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, RNA interference pipeline constitutes 20+ key companies continuously working towards developing 90+ RNA interference treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The RNA interference Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

RNA interference Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the RNA interference Market.

 

Some of the key takeaways from the RNA interference Pipeline Report:

  • Companies across the globe are diligently working toward developing novel RNA interference treatment therapies with a considerable amount of success over the years. 
  • RNA interference companies working in the treatment market are Olix Pharmaceuticals, Phio Pharmaceutic als, Siranomics, Arbutus Biopharma, Bio-Path Holdings, Vir Biotechnology, Alnylam Pharmaceuticals, Sylentis, and others, are developing therapies for the RNA interference treatment 
  • Emerging RNA interference therapies in the different phases of clinical trials are- OLX 703A, PH 894, STP707, AB-729, BP1001, VIR-2218, Cemdisiran, SYL1001, Lumasiran, and others are expected to have a significant impact on the RNA interference market in the coming years.   
  • In October 2022, Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, has announced that the U.S. Food and Drug Administration (FDA) has approved an expansion to the label for OXLUMO® (lumasiran), an RNAi therapeutic administered via subcutaneous injection. This expansion now includes an indication for treating primary hyperoxaluria type 1 (PH1) to reduce urinary oxalate (UOx) and plasma oxalate (POx) levels in both pediatric and adult patients. The FDA’s decision is supported by positive efficacy and safety findings from the ILLUMINATE-C Phase 3 study, which involved patients with severe renal impairment, including those receiving hemodialysis.
  • In October 2022, Regeneron Pharmaceuticals has commenced a Phase III clinical trial that is randomized and open-label, comparing pozelimab and cemdisiran in combination. This study aims to evaluate the safety and effectiveness of this therapy combination in patients diagnosed with paroxysmal nocturnal hemoglobinuria. These patients are currently undergoing treatment with eculizumab or ravulizumab. The trial is currently in an active phase and is not recruiting new participants. It is anticipated to conclude by June 2025.

 

RNA interference Overview

One of the mechanisms known as RNA silencing pathways, which use short RNAs as guides for sequence-specific silencing, is RNA interference (RNAi). Long double-stranded RNA (dsRNA)-induced sequence-specific mRNA degradation is known as RNAi, and it was first identified in C. elegans. In almost all human cells, the RNA interference (RNAi) pathway controls mRNA stability and translation.

 

Get a Free Sample PDF Report to know more about RNA interference Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/rna-interference-pipeline-insight

 

Emerging RNA interference Drugs Under Different Phases of Clinical Development Include:

  • OLX 703A: Olix Pharmaceuticals
  • PH 894: Phio Pharmaceutic als
  • STP707: Siranomics
  • AB-729: Arbutus Biopharma
  • BP1001: Bio-Path Holdings
  • VIR-2218: Vir Biotechnology
  • Cemdisiran: Alnylam Pharmaceuticals
  • SYL1001: Sylentis
  • Lumasiran: Alnylam Pharmaceuticals

 

RNA interference Route of Administration

RNA interference pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

 

RNA interference Molecule Type

RNA interference Products have been categorized under various Molecule types, such as

  • Oligonucleotide
  • Peptide
  • Small molecule

 

RNA interference Pipeline Therapeutics Assessment

  • RNA interference Assessment by Product Type
  • RNA interference By Stage and Product Type
  • RNA interference Assessment by Route of Administration
  • RNA interference By Stage and Route of Administration
  • RNA interference Assessment by Molecule Type
  • RNA interference by Stage and Molecule Type

 

DelveInsight’s RNA interference Report covers around 90+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further RNA interference product details are provided in the report. Download the RNA interference pipeline report to learn more about the emerging RNA interference therapies

 

Some of the key companies in the RNA interference Therapeutics Market include:

Key companies developing therapies for RNA interference are – Moderna Therapeutics, GenSight Biologics, Pfizer, bluebird bio, CureVac, ReGenX Biosciences, TransCode Therapeutics, Bicycle Therapeutics, and others.

 

RNA interference Pipeline Analysis:

The RNA interference pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of RNA interference with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for RNA interference Treatment.
  • RNA interference key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • RNA interference Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the RNA interference market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about RNA interference drugs and therapies

 

RNA interference Pipeline Market Drivers

Increasing prevalence of genetic disorders and other chronic medical conditions, diverse and extensive pipeline therapies, rise in the number of geriatric population are some of the important factors that are fueling the RNA interference Market.

 

RNA interference Pipeline Market Barriers

However, RNAi silencing method suffers from high off-target effects, high cost of research and development and other factors are creating obstacles in the RNA interference Market growth.

 

Scope of RNA interference Pipeline Drug Insight    

  • Coverage: Global
  • Key RNA interference Companies: Olix Pharmaceuticals, Phio Pharmaceutic als, Siranomics, Arbutus Biopharma, Bio-Path Holdings, Vir Biotechnology, Alnylam Pharmaceuticals, Sylentis, and others
  • Key RNA interference Therapies: OLX 703A, PH 894, STP707, AB-729, BP1001, VIR-2218, Cemdisiran, SYL1001, Lumasiran, and others
  • RNA interference Therapeutic Assessment: RNA interference current marketed and RNA interference emerging therapies
  • RNA interference Market Dynamics: RNA interference market drivers and RNA interference market barriers 

 

Request for Sample PDF Report for RNA interference Pipeline Assessment and clinical trials

 

Table of Contents

1. RNA interference Report Introduction

2. RNA interference Executive Summary

3. RNA interference Overview

4. RNA interference- Analytical Perspective In-depth Commercial Assessment

5. RNA interference Pipeline Therapeutics

6. RNA interference Late Stage Products (Phase II/III)

7. RNA interference Mid Stage Products (Phase II)

8. RNA interference Early Stage Products (Phase I)

9. RNA interference Preclinical Stage Products

10. RNA interference Therapeutics Assessment

11. RNA interference Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. RNA interference Key Companies

14. RNA interference Key Products

15. RNA interference Unmet Needs

16 . RNA interference Market Drivers and Barriers

17. RNA interference Future Perspectives and Conclusion

18. RNA interference Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Assessment of RNA Interference Pipeline and Clinical Trials in 2023: FDA Approvals, Therapeutics, and Companies by DelveInsight | Moderna Therapeutics, GenSight Biologics, Pfizer, bluebird bio

Smart Manufacturing Market Set for Exponential Growth, Predicted to Reach USD 241.0 Billion by 2028

“Smart Manufacturing Market”
The global Smart Manufacturing Market in terms of revenue was estimated to be worth $108.9 billion in 2023 and is poised to reach $241.0 billion by 2028, growing at a CAGR of 17.2% during the forecast period.

CHICAGO, Jan 08, 2024 – The global Smart Manufacturing Market is poised for unprecedented growth, with an anticipated surge from USD 108.9 billion in 2023 to USD 241.0 billion by 2028, reflecting an impressive Compound Annual Growth Rate (CAGR) of 17.2% during the forecast period. These insights are detailed in a comprehensive report by MarketsandMarkets, a leading market research and consulting firm.

The industrial landscape is changing due to smart manufacturing, which is defined by the incorporation of cutting-edge technologies and data-driven processes into production activities. Factors like the adoption of Industrial Internet of Things (IIoT), improvements in automation and robotics, and the quest of operational efficiency across industries are driving the predicted rise in the Smart Manufacturing market. The research analyses major competitors in the global smart manufacturing market and examines important market categories, growth factors, obstacles, and prospects.

Download PDF Brochure @ 
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=105448439

Smart Manufacturing Market

Key Segments:

Technology Segment: Smart Manufacturing encompasses various technologies, including IIoT, Artificial Intelligence (AI), robotics, 3D printing, and digital twin, each contributing to the digital transformation of manufacturing processes.

Component Segment: The market comprises different components, such as hardware (sensors, controllers, and industrial robots), software (Manufacturing Execution System, Enterprise Resource Planning), and services (consulting, system integration, and support services).

End-User Segment: Smart Manufacturing solutions cater to diverse end-user industries, including automotive, aerospace and defense, healthcare, chemical, and food and beverage, reflecting the broad applications across the manufacturing spectrum.

Inquiry Before Buying @
https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=105448439

Growth Drivers:

Adoption of Industrial IoT (IIoT): The widespread adoption of IIoT technologies, connecting machines, devices, and systems, contributes to real-time data analytics, predictive maintenance, and improved decision-making in manufacturing processes.

Advancements in Automation and Robotics: Continuous advancements in automation, robotics, and autonomous systems enhance manufacturing efficiency, reduce production costs, and enable flexible and agile production workflows.

Pursuit of Operational Efficiency: The increasing focus on achieving operational efficiency, reducing downtime, and optimizing resource utilization drives the implementation of Smart Manufacturing solutions across industries.

Challenges:

Data Security and Privacy Concerns: Addressing concerns related to data security and privacy in Smart Manufacturing environments poses challenges, requiring robust cybersecurity measures to safeguard sensitive information.

Integration with Legacy Systems: Ensuring seamless integration with existing legacy systems and machinery in manufacturing facilities may present challenges, requiring careful planning and compatibility assessments.

Opportunities:

Digital Transformation Initiatives: The ongoing digital transformation initiatives across industries create opportunities for Smart Manufacturing providers to offer tailored solutions for optimizing production processes and supply chain operations.

Customization for Industry-Specific Needs: The customization of Smart Manufacturing solutions to meet industry-specific requirements presents opportunities for manufacturers to provide specialized offerings for diverse manufacturing sectors.

View detailed Table of Content here –
https://www.marketsandmarkets.com/Market-Reports/smart-manufacturing-market-105448439.html

Key Players:

The report identifies key players in the global Smart Manufacturing market, including:

Siemens AG: A global technology company, providing a range of Smart Manufacturing solutions, including automation, digital twin, and Industrial IoT technologies.

General Electric Company: A multinational conglomerate, actively involved in the development of Smart Manufacturing solutions, including Predix, an industrial IoT platform.

ABB Ltd: A Swiss-Swedish multinational corporation, specializing in robotics, automation, and power technologies, contributing to the advancement of Smart Manufacturing.

Rockwell Automation, Inc.: A global provider of industrial automation and information solutions, offering a suite of Smart Manufacturing technologies and services.

Honeywell International Inc.: A multinational conglomerate, known for providing a variety of industrial solutions, including Smart Manufacturing technologies for process optimization.

Because of the revolutionary effect of digital technology on manufacturing processes and the unwavering pursuit of operational excellence, the global smart manufacturing industry is poised for exponential growth. Industry adoption of Smart Manufacturing concepts is expected to lead to increased innovation, efficiency, and competitiveness in the coming years.

Media Contact
Company Name: MarketsandMarketsâ„¢ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/smart-manufacturing-market-105448439.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Smart Manufacturing Market Set for Exponential Growth, Predicted to Reach USD 241.0 Billion by 2028

WBEC-West Announces 2023-2025 Board of Directors

WBEC-West Welcomes Distinguished Leaders to its Board of Directors

WBEC-West is pleased to announce the appointment of 6 New Board Members to its esteemed Board of Directors

  • Kate Kleyman, Social Impact Program Manager with McKinstry
  • Quentin O’Neal, Supplier Diversity Manager with Layton Construction
  • Deborah Mackins, Sr. Manager, Vendor Diversity with Arrow
  • Danielle Van Vleet, Sustainability and Diversity Program Manager with ASU
  • Catherine (Cat) Chang, Director, Office of the CFO with The Walt Disney Company
  • Kathleen Jones, Supplier Diversity Manager, BlueCross BlueShield –Arizona

“We are thrilled to welcome each of them to our Board of Directors,” said WBEC-West CEO Dr. Pamela Williamson. “Their collective expertise and passion for empowering women-owned businesses align seamlessly with our organization’s goals. We are confident that their contributions will play a pivotal role in advancing the impact of WBEC-West in the coming years.”

The new board members join a distinguished group of leaders committed to fostering economic growth, innovation, and equality for women entrepreneurs. Their induction reflects WBEC-West’s ongoing dedication to assembling a diverse and dynamic board that mirrors the rich tapestry of the communities it serves.

These seasoned professionals bring a wealth of experience, expertise, and commitment to furthering WBEC-West’s mission of advancing women-owned businesses.

WBEC-West is honored to announce the 2023-2025 Board of Directors are as follows:

Board Chair Tanya Nixon, Director, Supplier Diversity   Strategic Sourcing & Procurement l Corporate Services with AFLAC

Board Vice Chair – Lance Dorsey, Director, Supplier Diversity with Sony Pictures

Board Treasurer – Jennifer Trotter, Community Relations & DEI Manager with Plenary Group

Board Secretary – Ken Ashford, Business Outreach Representative for MWD

Board member + National Forum Rep

  • Lorelei Carobolante, President, and CEO of G2nd Systems
  • Rashmi Chaturvedi, President of Kaygen Information Excellence

Board Member

  • Katie Pendergrass, Vice President, Strategic Sourcing with Caesars Entertainment
  • Todd “TJ” Jackson, Manager, Supplier Diversity with Republic Services
  • Kristin Bentsen, Manager, Risk Management with AMGEN
  • Priscilla Chavez, Manager, Diversity & Inclusion with PCL Construction
  • Vaughn Williams III, Principal Supplier Diversity Advisor with SoCalGas
  • Joanne M. Florez, Supplier Diversity & Inclusion Program Manager with Intel
  • Stephen Kane, Vise President with Burns McDonnell
  • Lisa Stevens, Vice President, Minority Entrepreneurs, SR. Business Consultant with Chase for Business
  • Erika Castro, Supplier Diversity Program Manager with SRP
  • Brittney Parkinson, Community & Citizenship Director with Turner Construction
  • Kate Kleyman, Social Impact Program Manager with McKinstry
  • Quentin O’Neal, Supplier Diversity Manager with Layton Construction
  • Deborah Mackins, Sr. Manager, Vendor Diversity with Arrow
  • Danielle Van Vleet, Sustainability and Diversity Program Manager with ASU
  • Catherine (Cat) Chang, Director, Office of the CFO with The Walt Disney Company
  • Kathleen Jones, Supplier Diversity Manager, BlueCross BlueShield –Arizona

For more information about WBEC-West and its mission, please visit www.wbec-west.com

About Women’s Business Enterprise Council-West (WBEC-West) 

WBEC-West is a regional partner of the Women’s Business Enterprise National Council (WBENC), a coalition of corporations, WBEs, and regionally focused women’s business organizations. As an affiliate organization, WBEC-West implements the certification standards of WBENC throughout Arizona, Colorado, Southern California, Utah, Wyoming, Nevada, Hawaii, and Guam. WBENC is the largest certifier of women’s business enterprises in the U.S. and a leading advocate for women business owners, leaders, and entrepreneurs. WBENC certification is nationally recognized and accepted by more than 10,000 major corporations. We also support corporations in their efforts to include WBENC Certified WBEs in their supply chain.

Media Contact: office@wbec-west.org

Media Contact
Company Name: WBEC-West
Contact Person: Tera Jenkins
Email: Send Email
Phone: (480) 240-9473
Country: United States
Website: https://wbec-west.com/

Folding Mobility Scooters for Seniors & Adults

Folding mobility scooters have revolutionized travel for many individuals with limited mobility. These innovative vehicles are designed to combine the convenience of a traditional mobility scooter with the added benefit of portability. Easy to fold or dismantle without the need for tools, they cater to older adults and those with mobility impairments who require assistance for longer distances.

Folding mobility scooters have revolutionized travel for many individuals with limited mobility. These innovative vehicles are designed to combine the convenience of a traditional mobility scooter with the added benefit of portability. Easy to fold or dismantle without the need for tools, they cater to older adults and those with mobility impairments who require assistance for longer distances. With their lightweight and compact frames, these scooters often fit into the trunk of a car, making them an excellent choice for those who lead active lifestyles and wish to maintain their independence while on the go.

The market for folding mobility scooters has expanded, offering a range of models that differ in terms of speed, range, comfort, and ease of folding. Consumers can choose based on specific needs, whether they prioritize a scooter that is airline friendly, one with a long-range battery, or a model that offers ultra-lightweight construction for effortless transport. Safety features like adjustable armrests, swivel seating, and easy-to-use controls are common across various models, ensuring users can navigate with confidence.

As technology progresses, so does the functionality and efficiency of folding mobility scooters. Manufacturers are continuously improving design and performance, aiming to provide better service to those who rely on these devices for daily mobility. With consumer reviews and expert recommendations playing a pivotal role, individuals can now make informed decisions when selecting a folding mobility scooter that best suits their lifestyle and mobility requirements.

Understanding Folding Mobility Scooters

When considering a mobility scooter, folding models offer unique design features and benefits that cater to an on-the-go lifestyle, combining convenience with functionality.

Design and Mechanics

Folding mobility scooters are engineered to be compact and easy to transport. They typically consist of a lightweight frame that allows the scooter to collapse or fold without the need for tools. Some models, like the EV Rider Gypsy Q2, have an incredibly small footprint when folded, which can be as diminutive as 25 inches long, 16.5 inches wide, and 11 inches high. The mechanics ensure ease of folding, often involving simple pulling or pushing actions to ready the scooter for storage or use.

  • Key Design Aspects:

    • Small folded dimensions for storage and transport
    • Tool-free folding mechanics for ease of use
    • Lightweight frames, often made from aluminum
  • Popular Mechanics Examples:

    • Single-motion fold systems
    • Telescoping frames
    • Automatic folding capabilities available in some models like the Mojo Scooter

Benefits of Folding Models

The primary benefit of foldable mobility scooters is their convenience. They can be easily loaded into a vehicle’s trunk or taken on public transport, making them ideal for those who frequently travel. Their compact size is also beneficial for those living in smaller spaces. Furthermore, foldable models like the Glion SNAPnGO offer comfortable seating and robust support for individuals up to 300 pounds, ensuring that comfort isn’t sacrificed for the sake of portability.

  • Advantages of Folding Mobility Scooters:
    • Portability: Easily transported in cars, planes, and other forms of transport.
    • Storage: Occupy minimal space in storage areas.
    • Independence: Enhance the user’s autonomy and ability to travel.
    • Speed and Range: Maintain competitive maximum speeds and ranges on a single charge.

Mobility scooter folding mechanisms have revolutionized how individuals with mobility issues maintain their independence and navigate their environments. The blend of design ingenuity and practical benefits make foldable mobility scooters a compelling choice for many users.

Key Features to Consider

When selecting a folding mobility scooter, potential buyers should prioritize certain features that directly impact performance, convenience, and usability.

Weight and Portability

The weight of a scooter influences its portability. Lightweight mobility scooters, typically weighing under 60 pounds, are favored for their ease of transport. For frequent travelers, a light mobility scooter enhances mobility and independence.

  • Lightweight mobile scooter: Often less than 60 lbs
  • Portable mobility scooter: Designed for easy transportation
  • Travel mobility scooter: Compact when folded

Battery Life and Range

Battery life determines how far one can travel on a single charge. A robust battery is vital for users who spend extended periods of time away from charging sources. High-capacity batteries found in some scooters enable a range up to 35 miles.

  • Standard Lithium-Ion Battery: Offers longer life and range
  • Battery range: Can vary from model to model, with some offering up to 35 miles on a charge

Durability and Build Quality

Durability ensures the scooter withstands everyday use. Look for a scooter with a lifetime warranty on the frame for peace of mind. Never-flat wheels and a robust construction contribute to reliable stability and durability.

  • Lifetime warranty on frame: Indicator of a durable build
  • Never-flat wheels: Provide continuous stability

Ease of Folding Mechanism

An easy folding mechanism enhances the usability of a lightweight foldable mobility scooter. Models with automatic folding and unfolding via remote control simplify the process for users.

  • Automatic folding: Accessible through a remote control
  • Ease of folding: Essential for frequent folding and unfolding

Buyers should carefully compare these features against their individual needs to ensure they choose the most suitable folding mobility scooter.

The Best Folding Mobility Scooters

When selecting a folding mobility scooter, potential buyers must consider the weight, folding mechanism, and durability to ensure they choose a model that suits their lifestyle and mobility needs. Mobility Nest can help you find the perfect model.

High-End Models

High-end folding mobility scooters distinguish themselves with advanced features like automatic folding mechanisms, enhanced durability, and additional comfort options. The EV Rider Easy Move is noted for being both heavy-duty and relatively lightweight at 42 pounds, featuring a comfortable seat and LED light for visibility.

Budget-Friendly Options

Consumers seeking cost-effective mobility solutions can find several lightweight folding mobility scooter models that offer value without compromising quality. These scooters typically balance features and weight, aiming for optimal portability at a lower price point. A known model in this category features an easy manual folding mechanism and maintains a light weight to facilitate transport.

User Reviews and Recommendations

User testimonials and expert reviews are a crucial tool for measuring the real-world performance of folding mobility scooters. Buyers often highlight the importance of a scooter being lightweight and easy to fold without the use of tools for quick storage and transport. Models that receive frequent recommendations are generally those that strike an excellent balance between portability, user-friendly design, and cost efficiency.

Safety and Maintenance

Folding mobility scooters combine convenience with functionality, offering lightweight and portable solutions for those with mobility issues. Ensuring safety and proper maintenance is crucial for reliable operation.

Safety Features

Seatbelts: Folding mobility scooters often come equipped with seatbelts to secure the user in place, reducing the risk of injury due to falls or sudden movements.

Brakes: Reliable brakes are a safety must-have. They should be checked regularly to ensure they are responsive and not worn down.

Horn and Lights: A functioning horn and adequate lighting are essential for visibility and to alert others of the scooter’s presence, especially in low-light conditions.

Maintenance Tips

Battery Care:

  • Charging: Always turn off the scooter before charging. Connect the charger to the scooter’s designated point, then to a power outlet.
  • Storage: If the scooter will not be used for an extended period, store the battery according to the manufacturer’s recommendations.

Cleaning:

  • Wipe down surfaces with a damp cloth to keep the folding scooter clean from debris and dirt.
  • Avoid water exposure to electrical components.

Regular Checks:

  • Tires: Inspect for wear and ensure they are properly inflated.
  • Joints and Hinges: As folding scooters have moving parts for folding, regularly check these areas for wear or loose components.

Troubleshooting Common Issues

Battery Problems: If the scooter won’t start, check the battery’s charge level and connections. A battery that depletes quickly may require replacement.

Folding Mechanism: Should the scooter have difficulty folding or unfolding, inspect for obstructions or damage to the mechanism.

Motor Noise: Unusual sounds from the motor may indicate a need for professional servicing to avoid potential safety issues.

By adhering to these specific safety features and maintenance tips, users can ensure their folding mobility scooter remains a dependable mode of transportation.

Accessories and Customization

Folding mobility scooters offer enhanced convenience and portability, and equipping them with the right accessories can further improve their functionality and comfort. Users can personalize their scooters to better meet their individual needs through a variety of available accessories and customization options.

Essential Accessories

  • Armrests: Folding mobility scooters may be fitted with armrests to provide additional support and comfort, with some models like the ATTO offering armrest options for around $299.
  • Cushions: A range of seat cushions is available to boost comfort, with prices starting at $99 for standard ones and $149 for leather options.
  • Safety Accessories: To enhance visibility while on the move, accessories such as reflective materials can be added. Prices may vary based on the manufacturer.
  • Storage Solutions: Baskets and bags can be affixed to folding mobility scooters for added convenience, allowing users to carry personal items securely.

Customization Options

  • Seats: For an upgraded seating experience, luxury swivel seats made of leather are available starting at $150, providing both style and ease of movement.
  • Style Enhancements: A user can opt for foldable mobility scooters with unique color schemes or finishes to reflect personal taste.
  • Convenience Features: From phone holders to folding storage baskets, a scooter can be customized with parts aimed at making daily use more convenient. Pricing for these accessories is competitive, aiming to provide value to the user.

Traveling with a Folding Mobility Scooter

Traveling with a folding mobility scooter empowers individuals with mobility challenges to maintain their independence and freedom while on the move. They offer the convenience of transportability combined with the comfort necessary for daily activities.

Air Travel

When flying, travelers should look for airline-approved folding mobility scooters that are compact and lightweight. Most folding mobility scooters are designed to meet airline guidelines, such as the Buzzaround Carry-On which not only has a 300-pound weight capacity but also 18-mile battery range. It’s essential to check with the airline beforehand for specific policies regarding the storage and handling of mobility devices. Details such as weight restrictions, battery regulations, and if the scooter needs to be checked in or can be taken as a carry-on should be clarified.

Key points for air travel with a scooter:

  • Confirm airline mobility device policies in advance
  • Check battery requirements; lithium-ion batteries often have restrictions
  • Consider scooters that fold flat for ease of handling

Public Transportation

Using public transportation with a folding mobility scooter requires planning. Certain buses and trains have specific wheelchair-accessible spaces, and a travel folding mobility scooter should easily fit within these areas when folded. Space for maneuverability and designated areas for securing the scooter should be verified before travel.

Quick guide for public transportation:

  • Verify that the public transport is wheelchair-accessible
  • Check space availability for folding and securing the scooter

Vehicle Transport

For personal vehicle transport of a travel mobility scooter, the key factors are the folded size and weight of the scooter. Scooters such as the Ephesus S5 Electric Mobility Scooter and the Shoprider Echo are known for their ability to be easily folded and stored in the trunk or backseat of a car. Be aware of the dimensions and weight to ensure it fits in the available vehicle space. Some models may even come equipped with features that allow them to be pulled like luggage, adding an extra layer of convenience during vehicle transport.

Vehicle transport tips:

  • Ensure scooter dimensions are compatible with vehicle storage
  • Look for models with features for easy handling during loading and unloading

Legal Considerations

When considering a folding mobility scooter, it’s crucial to understand the regulatory environment and the importance of insurance policies and warranties. These legal aspects ensure compliance and provide protection for users.

Regulations and Laws

Folding mobility scooters, which can include small, compact, or mobility scooter compact models, are subject to various state and local regulations. In many areas, the following rules apply:

  • Speed Limits: Folding mobility scooters are generally limited to speeds of 8 miles per hour on the road to ensure they do not impede traffic flow.
  • Equipment Standards: They must often be equipped with lights, reflectors, and audible signals like horns or bells to be road-worthy.
    Equipment Requirement
    Lights Mandatory
    Reflectors Mandatory
    Horn/Bell Mandatory
  • Location Access: Usage may be restricted on certain roadways, such as interstates or roads with high speed limits, to safeguard the operators.

Insurance and Warranties

Insurance:

  • While not always legally required, obtaining insurance for a folding mobility scooter can provide liability cover and protect against damages.

Warranties:

  • Most scooters come with a manufacturer’s warranty. This generally covers the scooter for an initial period, which can range from six months to a few years, offering peace of mind regarding defects or operational issues.

Advancements in Folding Scooter Technology

The folding mobility scooter market has experienced significant technological advancements, leading to innovative solutions in both design and power efficiency. These developments have catered to the needs of adults who seek lightweight, portable, and convenient transportation modes.

Innovations in Design

Manufacturers have leveraged new materials and engineering insights to create collapsible mobility scooters that are both lightweight and durable. For instance, the integration of aircraft-grade aluminum frames has allowed these devices to support considerable weight while remaining easy to handle. Scooters like the Luggie Super Plus 4 Wheel showcase advanced folding technology, where users can effortlessly collapse the unit for storage or transportation, transforming the experience of mobility-challenged individuals.

The design focus has been on ergonomic features and compact dimensions that do not compromise on stability or functionality. A four-wheeled design, as seen in some of the latest models, offers improved balance and a safe ride, addressing the common concern about stability in lightweight mobility scooters for adults.

Battery and Charging Technologies

A pivotal aspect of these mobility scooters is their reliance on power efficiency and longevity in battery performance. Lithium-ion batteries have become the standard due to their high energy densities, which allow for longer usage times and quicker charging cycles. For example, certain models like the EV Rider Transport AF Plus come equipped with a 11.5ah lithium battery and promise a travel range of up to 10 miles on a single charge, making them ideal for travel without frequent recharging stops.

The emphasis on battery technology also includes ensuring compliance with regulations for travel. Lightweight mobility scooters are being designed with airline and cruise ship travel in mind, equipped with batteries that adhere to FAA guidelines for air travel. This feature ensures that users have fewer restrictions and more confidence when planning trips, contributing to an overall enhancement in lifestyle and mobility freedom.

Comparing Foldable to Traditional Mobility Scooters

When considering mobility assistance, the choice between a foldable mobility scooter and a traditional one largely depends on the user’s lifestyle and needs. Foldable scooters offer a compact, lightweight option that is often preferred for those with active, on-the-go lives.

Portability: Foldable mobility scooters are designed for ease of transport. They can typically be folded quickly, sometimes in seconds, and fit into car trunks with minimal effort. Traditional scooters, while sturdy, are bulkier and may require vehicle lifts for transportation.

Storage: A foldable mobile scooter stands out in its ability to be stored in small spaces, perfect for apartment living or for those with limited storage. In contrast, traditional scooters demand more storage space.

Weight: Foldable scooters are often more lightweight due to their compact and collapsible design. This can be advantageous for users who must frequently lift their scooters for transport or storage, while traditional scooters tend to be heavier, which adds to their stability but reduces portability.

Stability and Speed: Traditional mobility scooters generally offer better stability and higher weight capacity due to their larger size and more robust construction. While a lightweight mobility scooter foldable frame contributes to its portability, it may result in a lower weight limit and possibly reduced stability at higher speeds, compared to standard scooters.

Convenience for Travel: Foldable scooters shine in travel scenarios — they are easier to manage during airport transfers and can be more convenient on public transport. Traditional scooters might not be as travel-friendly but can be superior for extensive daily use due to their durability and longer battery life.

How to Choose the Right Folding Mobility Scooter

When selecting a folding mobility scooter, individuals must consider their personal mobility needs and seek guidance from healthcare professionals to ensure the best fit for their lifestyle.

Assessing Your Needs

One should first evaluate the primary environment in which the scooter will be used, be it indoors, outdoors, or a combination of both. If portability is paramount, lightweight mobility scooters are ideal. These scooters typically feature a compact design and can be folded easily to fit into a car trunk. The user should note the weight capacity and maximum speed of a scooter to ensure it aligns with their needs. A foldable lightweight mobility scooter emphasizes ease of transport and storage, making it a practical choice for those with an active lifestyle.

Consulting Healthcare Professionals

Before making a decision, consulting with a healthcare professional can provide valuable insight into the suitability of a particular scooter. They can assist in identifying the necessary features based on the user’s health condition, such as adjustable armrests or ergonomic seating for comfort. Healthcare professionals have the expertise to recommend a scooter that supports the user’s posture and provides the necessary stability and control they require.

Media Contact
Company Name: Mobility Nest
Contact Person: Cameron Heinz
Email: Send Email
Country: United States
Website: mobilitynest.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Folding Mobility Scooters for Seniors & Adults

Diamond Dogs Grooming Salon Highlights Its Two Convenient Locations in Naples, FL for the Upcoming Busy Season

Naples, FL – Diamond Dogs Grooming Salon, a beloved name in dog grooming services in Naples, FL, is excited to remind the community of its two strategically located salons as the busy season approaches. With facilities at 5628 Strand Blvd Unit 6, and 2400 Immokalee Rd, Diamond Dogs Grooming Salon is well-prepared to meet the increased demand for high-quality dog grooming services.

Two Locations, Double the Convenience

Both locations uphold the exceptional standard of care and service that Diamond Dogs Grooming Salon is known for. This dual presence in Naples allows for greater accessibility and convenience for all pet owners, ensuring that top-tier grooming services are just a short drive away, no matter where one resides in the city.

Ready for the Busy Season Rush

The busy season often sees a surge in grooming needs for pets. Diamond Dogs Grooming Salon’s two locations are a strategic response to this demand, offering more scheduling flexibility and shorter waiting times. This ensures that every pet receives prompt, attentive grooming services, even during the peak periods.

Expert Care in a Loving Environment

The team at Diamond Dogs Grooming Salon consists of skilled groomers who are passionate about animal care. They offer a variety of grooming services including baths, fur trimming, nail clipping, and specialized skin care treatments. Both salons are equipped to provide a comfortable, stress-free grooming experience for pets, ensuring they are treated with love and care.

A Strong Community Presence

As a locally owned business, Diamond Dogs Grooming Salon values its role in the Naples community. The presence of two salons in different parts of the city exemplifies their commitment to being accessible and convenient for all pet owners. It is this dedication to the community and their pets that has made Diamond Dogs Grooming Salon a go-to destination for dog grooming.

Visit Your Nearest Location

Pet owners are encouraged to visit the Diamond Dogs Grooming Salon nearest to them for exceptional grooming services. Appointments can be made by calling 239-325-9121 or 2392605847 additionally you can visit the salon’s website at diamonddogsnaples.com.

About Diamond Dogs Grooming Salon

With years of experience, Diamond Dogs Grooming Salon has established itself as a leading provider of dog grooming services in Naples, FL. Known for their professional, friendly approach and commitment to pet wellness, both salon locations are designed to offer a safe and comfortable grooming environment. Their continued success is a testament to their mission of delivering convenient, high-quality services to the local pet community.

Media Contact
Company Name: Diamond Dogs Grooming Salon
Contact Person: Michael Newton
Email: Send Email
Phone: 239-325-9121
Address:5628 Strand Blvd Unit 6
City: Naples
State: Florida
Country: United States
Website: https://diamonddogsnaples.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Diamond Dogs Grooming Salon Highlights Its Two Convenient Locations in Naples, FL for the Upcoming Busy Season